TradeFlare's AI research teams analysed APGE on 11 market nights between May 4, 2026 and September 4, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 4, 2026 | HOLD | $135.07 | — / — | not yet | not yet | The stock is awaiting a definitive catalyst related to its acquisition. |
| September 3, 2026 | HOLD | $135.07 | — / — | not yet | not yet | The stock is at a critical inflection point near its 52-week high with mixed signals, necessitating a HOLD to await clearer direction. |
| August 6, 2026 | BUY | $134.23 | — / — | not yet | not yet | The current setup does not meet the criteria for a buy recommendation due to risk and directional team alignment. |
| August 5, 2026 | BUY | $134.19 | — / — | not yet | not yet | Positive clinical trial data readouts for lead drug candidates. |
| June 30, 2026 | BUY | $132.61 | — / — | not yet | not yet | Potential acquisition by AbbVie provides a clear upside catalyst. |
| June 25, 2026 | BUY | $132.69 | — / — | not yet | not yet | Pending acquisition by AbbVie provides a clear takeout premium. |
| May 14, 2026 | BUY | $83.94 | — / — | not yet | not yet | Positive clinical trial data for zumilokibart. |
| May 13, 2026 | BUY | $82.93 | — / — | not yet | not yet | Successful progression of APG-777 through clinical trials for atopic dermatitis and asthma. |
| May 6, 2026 | HOLD | $83.29 | — / — | not yet | not yet | Positive clinical trial data for lead drug candidate. |
| May 5, 2026 | SELL | $83.55 | — / — | not yet | not yet | Continued positive clinical trial data for APG777. |
| May 4, 2026 | SELL | $80.75 | — / — | not yet | not yet | Positive clinical trial data for Zumilokibart. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.